CMA: pay-for-delay settlement “restrictive in its own right”

In its opening statement at the Competition Appeal Tribunal today, the UK competition authority said that pay-for-delay agreements between an antidepressant patent holder and generics manufacturers were “by nature antithetical to the competitive process”.

Get unlimited access to all Global Competition Review content